Trevena, Inc. (TRVN)
Description:
Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the
Sector:
Industry:
Analyst An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company. |
Research Firm A Research Firm is a company that researches and rates stocks and publishes recommendations. |
Signal Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL. |
Signal Date A signal date is a date when a BUY or SELL recommendation was issued for given security. |
Initial Price Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted. |
Price Target A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position. |
Closing Date Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months. |
Return The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits). |
---|---|---|---|---|---|---|---|
Jason Butler | JMP Securities | Buy | Feb 05, '19 | 4.00 | Feb 05, '20 | N/A | |
Ed Arce | Mcnicoll, Lewis, & Vlak | Buy | Oct 12, '18 | 3.00 | Oct 12, '19 | N/A | |
Jason Butler | JMP Securities | Buy | Oct 10, '18 | 15.00 | Oct 10, '19 | N/A | |
Ritu Baral | Canaccord Genuity | Buy | Sep 04, '18 | 10.00 | Sep 04, '19 | N/A | |
Jason Butler | JMP Securities | Buy | Aug 20, '18 | 15.00 | Aug 20, '19 | N/A | |
Ed Arce | Mcnicoll, Lewis, & Vlak | Buy | Aug 13, '18 | 7.00 | Aug 13, '19 | N/A | |
Ritu Baral | Canaccord Genuity | Buy | Jun 05, '18 | 10.00 | Jun 05, '19 | N/A | |
Ed Arce | Mcnicoll, Lewis, & Vlak | Buy | Mar 08, '18 | 7.00 | Mar 08, '19 | N/A | |
Alan Carr | Needham & Company | Buy | Nov 07, '17 | 7.00 | Nov 07, '18 | N/A | |
Ed Arce | Mcnicoll, Lewis, & Vlak | Buy | Oct 12, '17 | 7.00 | Oct 12, '18 | N/A | |
Ritu Baral | Canaccord Genuity | Buy | Aug 03, '17 | 10.00 | Aug 03, '18 | N/A | |
Alan Carr | Needham & Company | Buy | Aug 03, '17 | Aug 03, '18 | N/A | ||
Ed Arce | Mcnicoll, Lewis, & Vlak | Buy | Jul 21, '17 | 8.00 | Jul 21, '18 | N/A | |
Alan Carr | Needham & Company | Buy | Feb 21, '17 | 11.00 | Feb 21, '18 | N/A | |
Ritu Baral | Canaccord Genuity | Buy | Jan 25, '17 | 13.00 | Jan 25, '18 | N/A | |
Biren Amin | Jefferies & Co. | Buy | Nov 03, '16 | 11.00 | Nov 03, '17 | N/A | |
Jonathan Aschoff | Brean Murray, Carret & Co. | Buy | Mar 09, '16 | 7.71 | 14.00 | Mar 09, '17 | -54.22% |
Jason Butler | JMP Securities | Buy | Mar 09, '16 | 7.71 | 18.00 | Mar 09, '17 | -54.22% |
Biren Amin | Jefferies & Co. | Buy | Feb 22, '16 | 9.71 | 15.00 | Feb 22, '17 | -56.02% |
Ritu Baral | Canaccord Genuity | Buy | Feb 22, '16 | 9.71 | 14.00 | Feb 22, '17 | -56.02% |